ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue
- Author(s)
- Mersiades, AJ; Solomon, BJ; Thomas, DM; Lee, CK; Cummins, MM; Sebastian, L; Ballinger, ML; Collignon, E; Turnbull, OM; Yip, S; Morton, RL; Brown, C; Wheeler, PJ; Itchins, M; Simes, RJ; Pavlakis, N;
- Details
- Publication Year 2024-03,Volume 20,Issue #7,Page 361-371
- Journal Title
- Future Oncology
- Publication Type
- Research article
- Abstract
- ASPiRATION is a national prospective observational cohort study assessing the feasibility, clinical and economic value of up-front tissue-based comprehensive genomic profiling (CGP) to identify actionable genomic alterations in participants with newly diagnosed metastatic non-squamous non-small-cell lung cancer in Australia. This study will enrol 1000 participants with tumor available for CGP and standard of care molecular testing (EGFR/ALK/ROS1). Participants with actionable variants may receive novel targeted treatments through ASPiRATION-specific substudies, other trials/programs. Clinical outcome data will be collected for a minimum of 2 years. Study outcomes are descriptive, including the ability of CGP to identify additional actionable variants, leading to personalized treatment recommendations, and will describe the feasibility, efficiency, cost and utility of implementation of CGP nationally.; Lung cancer is the most common cause of cancer death in Australia and worldwide. This disease often happens due to alterations in specific genes that allow cancer cells to develop and spread. Scientists have designed targeted drugs that are better at attacking cancer cells that have specific ‘actionable’ gene alterations and have less effect on other cells in the body. The result is often more benefit from treatment and fewer side effects than other standard treatments (chemotherapy or immunotherapy). The targeted drugs are well established as the best initial treatments for some gene alterations, but more research is needed to know if this is true for some of the less common or recently identified gene alterations, and where the targeted drugs are very new. Comprehensive genomic profiling is a new way of testing lung cancer cells for all the gene alterations (the well-known ones as well as the rare ones) in a single test. It is expected that this test will find many more of these gene alterations, which will allow more people to have safer and more effective targeted treatments leading to potentially better outcomes, and will allow some people to join clinical trials testing newer targeted treatments. The ASPiRATION study will help work out whether comprehensive genomic profiling is better than the current way of testing for gene alterations in Australia, and if it is feasible to use in all people diagnosed with advanced lung cancer in Australia. Clinical Trial Registration: ACTRN12621000221853 (ANZCTR).; eng
- Publisher
- Future Medicine
- Keywords
- Humans; *Lung Neoplasms/pathology; *Carcinoma, Non-Small-Cell Lung/drug therapy; Prospective Studies; Protein-Tyrosine Kinases/genetics; Mutation; Australia; Proto-Oncogene Proteins/genetics; Genomics; Observational Studies as Topic; Nsclc; biomarkers; comprehensive genome profiling; genomic alterations; lung cancer; precision oncology
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.2217/fon-2023-0366
- Open Access at Publisher's Site
https://doi.org/10.2217/fon-2023-0366- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-04-09 12:02:07
Last Modified: 2024-04-09 12:02:24